How PBI/Gordon Companies leveraged our Sirolimus API Market report
VM Intelligence · Sample preview · Healthcare and Pharmaceuticals · Forecast 2027–2033
Organ and Tissue Transplantation Market
- By Organ Type: Kidney Transplant, Liver Transplant, Heart Transplant, Lung Transplant, Pancreas Transplant, Intestinal Transplant
- By Tissue Type: Corneal Transplant, Skin Grafting, Bone Grafting, Heart Valve Transplant, Tendon and Ligament Transplant
- By Donor Type: Living Donor, Deceased Donor, Autologous Transplant
- By End User: Hospitals, Specialized Transplant Centers, Ambulatory Surgical Centers
- By Transplant Procedure: Allogeneic Transplantation, Xenotransplantation, Islet Cell Transplantation
Key Highlights
A snapshot of what the full report proves- 01 Market size - $X,XXX.XM global market in 2025 - the verified base-year revenue. Executive Summary →
- 02 Forecast - Full 2033 market projection modelled inside - unlock the forecast value to see where the market lands. Market Outlook →
- 03 Growth - Year-by-year CAGR across 2027–2033 - unlock the growth rate and the full model. Market Outlook →
- 04 Leading segment - Kidney Transplant leads By Organ Type at XX% share. Market, by Service Type →
- 05 Global coverage - Sized across 5 regions and 20 countries, each broken out by segment. Market, by Geography →
- 06 Competitive landscape - 15 companies profiled with SWOT, benchmarking and market-share analysis. Company Profiles →
Inside the Report
12 chapters · 294 pages- 01 Introduction Definition, segmentation & scope p.12 →
- 02 Research Methodology How the numbers were built p.20 →
- 03 Executive Summary The market in one chapter p.34 →
- 04 Market Outlook Drivers, restraints, trends p.66 →
- 11 Competitive Landscape 5 sections p.178 →
- 12 Company Profiles 15 players: SWOT & benchmarking p.186 →
Full report · locked preview
Everything inside the Organ and Tissue Transplantation Market report
A complete, evidence-based study - 12 chapters and 123 sections covering market size, segmentation across 5 axes, regional analysis and 15 company profiles, forecast to 2033.
Segmentation covered
Organ Type 6
Tissue Type 5
Donor Type 3
End User 3
Transplant Procedure 3
Companies profiled
Organ Recovery Systems Inc.
LifeCell Corporation (Apart of Allergan)
MiMedx Group Inc.
RTI Surgical Inc.
Osiris Therapeutics Inc.
Aziyo Biologics Inc.
CryoLife Inc.
Medtronic plc
Stryker Corporation
Baxter International Inc.
Terumo Corporation
Cook Medical
+3 more
Verified · Analyst-reviewed · No payment to preview
Trusted & certified by
★★★★★ Excellent
★★★★★ Excellent
15 players profiled - tiered by revenue contribution, footprint and R&D capability.
ACE Matrix · p.153 →Organ Recovery Systems Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.155 →LifeCell Corporation (Apart of Allergan)
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.160 →MiMedx Group Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.166 →RTI Surgical Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.173 →Osiris Therapeutics Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.178 →Aziyo Biologics Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.184 →CryoLife Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.191 →Medtronic plc
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.196 →Stryker Corporation
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.202 →Baxter International Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.209 →Terumo Corporation
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.214 →Cook Medical
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.220 →Organovo Holdings Inc.
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.227 →TransMedics Inc.
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.232 →XVIVO Perfusion AB
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.238 →Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Global · 2025–2033
$9,857M by 2033 · 11.0% CAGR
Market estimates & forecast (USD Million)
Fig. 15 · p.34 →Segment mix, 2033 (% share)
Fig. 16 · p.35 →- Kidney Transplant37.0
- Liver Transplant12.9
- Heart Transplant8.6
- Lung Transplant10.0
- Pancreas Transplant12.1
- Intestinal Transplant19.5
Regions, 2025 → 2033 (USD Mn)
§6.1 · p.75 →North America$1,407M → $3,139M · 10.6%
Europe$980.5M → $2,043M · 9.6%
Asia Pacific$895.3M → $1,942M · 10.2%
Latin America$554.2M → $1,326M · 11.5%
Middle East and Africa$426.3M → $1,036M · 11.7%
Top countries, 2033 (USD Mn)
§6.2 · p.78 →Year-over-year growth (%)
§3.12 · p.44 →10.992026
11.002027
11.022028
11.022029
11.042030
11.052031
11.072032
11.092033
CAGR by region (%)
Fig. 22 · p.71 →Market share by company, 2033 (%)
Fig. 41 · p.152 →- Organ Recovery Systems Inc.19.5
- LifeCell Corporation (Apart of Allergan)19.8
- MiMedx Group Inc.8.5
- RTI Surgical Inc.9.7
- Osiris Therapeutics Inc.8.5
- Aziyo Biologics Inc.5.9
- Others28.1
Segment contribution to growth (%)
Fig. 18 · p.39 →Organ Type16.6%
Tissue Type14.7%
Donor Type22.7%
End User22.9%
Transplant Procedure23.1%
Competitive positioning (ACE matrix)
Fig. 40 · p.153 →Adoption & penetration (% of addressable)
Fig. 12 · p.31 →Revenue by application (USD Mn)
§5.3 · p.62 →Demand by end-use (USD Mn)
§5.4 · p.66 →Average selling price trend (index, 2025=100)
Fig. 27 · p.58 →Top companies by revenue, 2033 (USD Mn)
Fig. 42 · p.155 →Revenue by region, 2033 (%)
Fig. 20 · p.70 →- North America33.1
- Europe21.5
- Asia Pacific20.5
- Latin America14.0
- Middle East and Africa10.9
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
8 players benchmarked across 6 dimensions — scored 0–100 from share, portfolio, reach, innovation, financials and installed base. Methodology · §8.1 · p.160 →
Competitive scorecard (score 0–100)
Table 31 · p.161 →| Company | Market share | Product portfolio | Geographic reach | Innovation & R&D | Financial strength | Customer base | Composite |
|---|---|---|---|---|---|---|---|
| Organ Recovery Systems Inc. | 80 | 88 | 94 | 85 | 96 | 79 | 87 |
| LifeCell Corporation (Apart of Allergan) | 81 | 89 | 80 | 71 | 71 | 69 | 77 |
| MiMedx Group Inc. | 68 | 66 | 72 | 86 | 81 | 67 | 73 |
| RTI Surgical Inc. | 80 | 68 | 79 | 60 | 72 | 58 | 70 |
| Osiris Therapeutics Inc. | 56 | 71 | 52 | 58 | 60 | 58 | 59 |
| Aziyo Biologics Inc. | 55 | 69 | 62 | 51 | 48 | 55 | 57 |
| CryoLife Inc. | 48 | 56 | 61 | 45 | 50 | 58 | 53 |
| Medtronic plc | 35 | 60 | 44 | 36 | 53 | 52 | 47 |
Vendor positioning (presence × innovation)
Fig. 43 · p.163 →Strengths profile (top 3 players)
Fig. 44 · p.165 →- Organ Recovery Systems Inc.
- LifeCell Corporation (Apart of Allergan)
- MiMedx Group Inc.
Capability coverage
§8.3 · p.168 →| Company | Global delivery | R&D depth | Digital platform | Sustainability | After-sales | Custom solutions |
|---|---|---|---|---|---|---|
| Organ Recovery Systems Inc. | ✓ | ◐ | ✓ | ✓ | ✓ | ✓ |
| LifeCell Corporation (Apart of Allergan) | ◐ | ◐ | ◐ | ✓ | ◐ | ◐ |
| MiMedx Group Inc. | ◐ | ◐ | ◐ | ✓ | ✓ | ◐ |
| RTI Surgical Inc. | ✓ | ✓ | ◐ | ◐ | − | − |
| Osiris Therapeutics Inc. | ◐ | ◐ | − | − | ◐ | ◐ |
| Aziyo Biologics Inc. | − | ✓ | − | − | ◐ | − |
| CryoLife Inc. | ◐ | − | − | − | ◐ | − |
| Medtronic plc | − | ✓ | − | − | ◐ | − |
✓ Full ◐ Partial − Limited
Overall competitive index (composite, ranked)
Fig. 45 · p.170 →1Organ Recovery Systems Inc.87
2LifeCell Corporation (Apart of Allergan)77
3MiMedx Group Inc.73
4RTI Surgical Inc.70
5Osiris Therapeutics Inc.59
6Aziyo Biologics Inc.57
7CryoLife Inc.53
8Medtronic plc47
Competitive tiers
§8.4 · p.172 →Leader1
Set the pace on share, breadth and innovation.
Organ Recovery Systems Inc.
Challenger3
Strong scale, closing on the leaders.
LifeCell Corporation (Apart of Allergan)MiMedx Group Inc.RTI Surgical Inc.
Contender2
Focused players with pockets of strength.
Osiris Therapeutics Inc.Aziyo Biologics Inc.
Niche2
Specialists in a single segment or region.
CryoLife Inc.Medtronic plc
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Go-to-market strategy
Land Organ Type in North America, then scale across Organ and Tissue Transplantation Market — a $538M beachhead inside a $8.80B market.
Beachhead (SOM)$538Mobtainable near-term
Serviceable (SAM)$3.35Breachable market
Primary motionDirect + partner-ledgo-to-market
Time to scale5 Qto full motion
Ideal customer profile (who to sell to)
§GTM 1 · p.190 →Champion89 fit
Kidney Transplant
Best fit — highest urgency & budget in Organ Type.
Economic buyer77 fit
Liver Transplant
Strong fit — clear ROI and a fast path to value.
End user69 fit
Heart Transplant
Emerging fit — growing demand, longer sales cycle.
Market-entry sequence (beachhead → scale)
Fig. GTM 1 · p.192 →Beachhead · 2025–2026
Win Organ Type in North America
Concentrated ICP, fastest proof and references.
Expand · 2026–2028
Add Tissue Type & next regions
Repeat the motion in adjacent, look-alike segments.
Scale · 2028–2033
Full-market coverage + Donor Type
Multi-channel, platform & ecosystem plays.
Channel mix (routes to market)
§GTM 3 · p.195 →Direct sales45%
Partner / channel29%
Digital / self-serve18%
Marketplaces7%
Positioning & messaging
§GTM 2 · p.194 →For Organ Type leaders who need defensible market intelligence, VM Intelligence is the fastest, source-cited way to size, segment and win Organ and Tissue Transplantation Market — unlike generic, static research.
Live & source-cited
Every figure triangulated from 600K+ sources and traceable.
Ready in minutes
A full, tailored report compiled on demand — not weeks.
Scope you control
Pick the chapters, regions and companies that matter.
GTM funnel & unit economics (conversion · CAC / LTV)
Fig. GTM 2 · p.198 →Awareness100%
Marketing qualified45%
Sales qualified21%
Evaluation12%
Closed-won7%
$10.7KCAC
$37KLTV
3.4:1LTV : CAC
< 4 moCAC payback
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Investment thesis
Organ and Tissue Transplantation Market is a durable-growth opportunity — $1.29B by 2033, compounding at 6.4%.
TAM · 2025$783Mtoday
TAM · 2033$1.29Bforecast
CAGR6.4%2027–2033
Cumulative$9.16Brevenue opportunity
Market opportunity (TAM · SAM · SOM)
Fig. 3 · p.14 →TAM$1.29BTotal addressable market
SAM$523MServiceable available market
SOM$88MServiceable obtainable market
Growth trajectory (USD Million)
Fig. 4 · p.16 →Why invest now
§2.1 · p.10 →6.4% CAGR
Demand compounds through 2033, outpacing GDP across Organ Type.
Global tailwinds
North America leads today; fastest gains coming from emerging regions.
Structural shift
Adoption in Organ Type moving from early to mainstream — durable secular demand.
Consolidation upside
15+ players, no runaway leader — room to build scale and roll up share.
Investment highlights
§2.2 · p.12 →$1.29BLarge & growingTAM by 2033 at 6.4% CAGR
$523MServiceable nowreachable with today’s model
$88MBeachhead winobtainable near-term share
15+Fragmented fieldplayers — consolidation runway
Return scenarios (2033 market value)
Fig. 6 · p.22 →$1.01BBear4.2% CAGR
$1.29BBase6.4% CAGR
$1.65BBull8.5% CAGR
Key risks & mitigants
§9.1 · p.180 →- Input-cost volatilityLong-term supply contracts & hedging
- Regulatory / policy shiftsDiversified exposure across 5 regions
- Technology disruptionR&D pipeline & Tissue Type optionality
- Customer concentrationBroaden installed base beyond top accounts
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Board pack · executive summary
Organ and Tissue Transplantation Market — a $1.69B market by 2033. Plan: grow share from 8.7% to 13.8%.
Market size · 2033$1.69Btotal addressable
Market CAGR8.2%2027–2033
Target share13.8%from 8.7% today
Revenue ambition$233Mby 2033
Strategic scorecard (current vs 2033 target)
Table 1 · p.6 →| Objective | Current | Target · 2033 | Status |
|---|---|---|---|
| Market share | 8.7% | 13.8% | On track |
| Revenue | $160M | $233M | Behind |
| Geographic coverage | 2 of 5 regions | 5 of 5 regions | On track |
| Segment coverage | 3 of 5 axes | 5 of 5 axes | Behind |
| Gross margin | 33.7% | 38.4% | On track |
| Customer retention | 88.0% | 95.8% | On track |
Where to play (strategic priorities)
§1.2 · p.8 →1
Lead segment
Win in Organ Type
Largest revenue pool and fastest secular demand — concentrate to build share here first.
2
Geographic
Expand across North America & beyond
Deepen the leading region, then scale into the fastest-growing emerging markets.
3
Adjacency
Build Tissue Type capability
A defensible second engine — invest in Tissue Type to widen the moat and cross-sell.
Strategic roadmap (2025–2033)
Fig. 1 · p.10 →Phase 1 · Foundation
2025–2027
- Secure core Organ Type share
- Fix unit economics
- Stand up data & ops
Phase 2 · Scale
2028–2030
- Enter new regions
- Launch Tissue Type
- Selective M&A
Phase 3 · Lead
2031–2033
- Category leadership
- Premium mix & margin
- Platform & ecosystem
Board decisions & asks
§1.4 · p.14 →- Approve $24M capacity & capability investment
- Greenlight bolt-on M&A in Tissue Type
- Authorise North America expansion plan
- Fund R&D program for Organ Type leadership
Risk watchlist (RAG)
§9 · p.180 →- Demand / macro slowdownOn track
- Competitive share lossAt risk
- Input-cost & supply riskOn track
- Regulatory / policy changeAhead
- Execution & talentBehind
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Sales deck · value proposition
Win the Organ and Tissue Transplantation Market conversation — a $6.88B market you can size, segment and defend in minutes.
Market size · 2033$6.88Btotal opportunity
Growth4.7%CAGR to 2033
Addressable buyers972+accounts in scope
Typical ROI5.9×in year one
Who buys (target personas)
§1.1 · p.4 →Product / BU leader
Head of Organ Type
Goal Grow share in Organ Type
Pain Blind spots on demand, pricing & competitors.
Regional GM
North America lead
Goal Prioritise the right markets
Pain No granular, country-level view of the market.
M&A / strategy
Strategy & Corp Dev
Goal Find where to invest or acquire
Pain Slow, inconsistent third-party research.
From pain to solution
§1.2 · p.6 →Decisions made on stale, generic dataLive, source-cited figures, continuously updated
Weeks waiting on a research vendorA full report compiled in minutes
No view of competitors or whitespaceCompany profiles, ACE matrix & benchmarking
Hard to defend the numbers internallyEvery figure traceable to its original source
The business case (ROI)
Fig. 2 · p.9 →5.9×return on cost, year one
< 4 mopayback period
$74K+research cost avoided
10×faster than a custom study
Time to insight
Cost to run
Risk of a wrong call
Why buyers trust it (proof points)
§1.3 · p.12 →600K+source studies indexed
100%analyst-reviewed
15+players profiled in this market
Coverage includes
Organ Recovery Systems Inc.LifeCell Corporation (Apart of Allergan)MiMedx Group Inc.RTI Surgical Inc.Osiris Therapeutics Inc.Aziyo Biologics Inc.CryoLife Inc.Medtronic plc+7 more
Objection handling
§1.4 · p.14 →“We already have market data.”
This triangulates 600K+ sources into one current, defensible view — not another silo.
“How do we know it’s accurate?”
Analyst-reviewed, and every figure is source-cited and traceable to its origin.
“It’s not in the budget.”
A fraction of a single analyst-day — and it pays back on the first decision it informs.
“We need it tailored to us.”
Choose the chapters, regions and companies before you build — you only pay for scope.
What you get (packages)
§1.5 · p.16 →Report
- Full multi-chapter report
- Market size, share & forecast
- Segment & regional breakdowns
- PDF + editable Excel + PPT
Most popular
Report + Add-ons
- Everything in Report
- Interactive Visualizer
- Competitive benchmarking
- Investor / board / sales decks
Enterprise
- Multiple reports & markets
- Team seats & sharing
- Analyst support & custom scope
- API / data-feed options
Almost there
Access your Organ and Tissue Transplantation Market report
Sign in to unlock the full report - it’s compiled live and ready in minutes.
or continue with your email
Your report is ready to access
Organ and Tissue Transplantation Market Report is ready
Verify your email to unlock it. We sent a 6-digit code to your inbox.
That code is invalid or expired. Please try again.
Trusted by strategy, finance & consulting teams
Related Reports
Healthcare and Pharmaceuticals · scroll →Orthopedic Instrumentation Market
Market size, share, segmentation and regional forecast.
$1.5B market · 2025 base year
View reportOrthopedic Prosthetic Implants Market
Market size, share, segmentation and regional forecast.
$2.5B market · 2025 base year
View reportOsteoporosis Therapeutics Market
Market size, share, segmentation and regional forecast.
$4.5B market · 2025 base year
View reportOvarian Cancer Therapeutics Market
Market size, share, segmentation and regional forecast.
$2.3B market · 2025 base year
View reportOveractive Bladder (OAB) Therapeutics Market
Market size, share, segmentation and regional forecast.
$6.1B market · 2025 base year
View reportPacemakers Market
Market size, share, segmentation and regional forecast.
$1.7B market · 2025 base year
View reportPain Management Market
Market size, share, segmentation and regional forecast.
$2.9B market · 2025 base year
View reportPathogen Testing Market
Market size, share, segmentation and regional forecast.
$2.4B market · 2025 base year
View reportPeptic Ulcer Testing Market
Market size, share, segmentation and regional forecast.
$4.6B market · 2025 base year
View reportHand held Veterinary Refractometers Market
Market size, share, segmentation and regional forecast.
$5.7B market · 2025 base year
View reportHead and Neck Cancer Therapeutics Market
Market size, share, segmentation and regional forecast.
$1.3B market · 2025 base year
View reportHealth Caregiving Market
Market size, share, segmentation and regional forecast.
$746M market · 2025 base year
View reportThe showdown
Custom-built vs. off-the-shelf
Scroll to watch them go head-to-head
WinnerVMR Custom Report
- Tailored to your exact scope
- Delivered in minutes
- Live, always-current data
- Fully editable data (XLSX)
- You choose the companies
- Source-cited & traceable
Off-the-shelf PDF
- Generic, one-size template
- Waits 2–5 days
- A fixed snapshot in time
- Locked, flat PDF
- Preset company list
- Opaque sourcing
Customer Testimonials
Proof from industry leaders who rely on us
These stories come from the executives who depend on VMR’s intelligence for market entry, expansion, assessment, and planning. Their outcomes and experiences reflect our commitment to clarity.
600,000+source studies indexed
100%analyst-reviewed
Every figuresource-cited & traceable
In their words
Watch clients tell their story
How VMR helped University of Limerick with Anesthesia Monitoring Devices
How VMR helps brands expand into Africa & emerging markets
Unlock your GTM strategy: an Elsewedy Electric success story
Beyond sales data: layering NielsenIQ data to support strategy
How VMR became the trusted partner for United Alloy
Questions, answered
How is the research actually conducted?
Every report is compiled from VMR’s continuously-updated intelligence across 600,000+ source studies - primary interviews, company filings, trade data, and government & industry databases. Figures are triangulated across multiple credible sources, then reviewed by a research analyst before your report is delivered.
What exactly do I get inside the report?
A full multi-chapter study: market definition & methodology, executive summary, market outlook (drivers, restraints, trends, Porter’s Five Forces), segment deep-dives, regional & country breakdowns, competitive landscape, and a full profile for every company you select - with interactive charts and data tables throughout.
How accurate are the numbers, and can I trust them?
Market sizing is reconciled across leading sources (Gartner, BCG, MarketsandMarkets, government bodies and more), with outliers removed and a confidence-graded median used for the base year. Every figure is source-cited and traceable to its origin, and an analyst validates the model before delivery.
Can I customise the chapters, regions and companies?
Yes. Choose exactly the chapters, regions and countries, and the companies you want benchmarked before you build - then adjust your selection and recompile anytime from your account. You only pay for the scope you need.
What formats do I receive, and is the data editable?
Every report is readable online in full. Downloadable formats are available as optional $99 add-ons: a formatted PDF and a fully editable XLSX containing all underlying data tables - so you can re-chart, re-model, or drop any figure straight into your own deck.